Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors

Purpose Vγ9Vδ2 (γδ) T lymphocytes, a critical peripheral blood lymphocyte subset, are directly cytotoxic against many solid and hematologic tumor types. Vγ9Vδ2 T lymphocytes can be selectively expanded in vivo with BrHPP (IPH1101) and IL-2. The present phase I trial was conducted with the aim of det...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer Immunology, Immunotherapy Immunotherapy, 2010-10, Vol.59 (10), p.1521-1530
Hauptverfasser:	Bennouna, Jaafar, Levy, Vincent, Sicard, Hélène, Senellart, Hélène, Audrain, Marie, Hiret, Sandrine, Rolland, Frédéric, Bruzzoni-Giovanelli, Heriberto, Rimbert, Marie, Galéa, Céline, Tiollier, Jérome, Calvo, Fabien
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Biological and medical sciences Bromohydrin pyrophosphate Cancer Research Immunology Immunotherapy Medical sciences Medicine Medicine & Public Health Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Oncology Original Original Article Pharmacology. Drug treatments Phase I trial Solid tumors Tumors Vγ9Vδ2 T lymphocyte
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!